Should decisions on adding adjuvant chemotherapy in early-stage ER-positive breast cancer be based on gene expression testing or clinicopathologic factors or both?

D. B. Geffen

doi:10.1093/annonc/mdy115

Should decisions on adding adjuvant chemotherapy in early-stage ER-positive breast cancer be based on gene expression testing or clinicopathologic factors or both?

D. B. Geffen

Research output: Contribution to journal › Editorial

6 Scopus citations

Original language	English
Pages (from-to)	1096-1098
Number of pages	3
Journal	Annals of Oncology
Volume	29
Issue number	5
DOIs	https://doi.org/10.1093/annonc/mdy115
State	Published - 1 May 2018

ASJC Scopus subject areas

Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdy115

Cite this

@article{7816f90c76f1413591c2a1ca82ff873b,

title = "Should decisions on adding adjuvant chemotherapy in early-stage ER-positive breast cancer be based on gene expression testing or clinicopathologic factors or both?",

author = "Geffen, {D. B.}",

year = "2018",

month = may,

day = "1",

doi = "10.1093/annonc/mdy115",

language = "English",

volume = "29",

pages = "1096--1098",

journal = "Annals of Oncology",

issn = "0923-7534",